4.6 Article

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

出版社

WILEY
DOI: 10.1111/jdv.18220

关键词

-

资金

  1. European Academy of Dermatology and Venereology (EADV)
  2. European Network for Rare Skin Disorders (ERN)

向作者/读者索取更多资源

The background provides detailed information about bullous pemphigoid (BP) and its impact on patients. The objective of the study is to update the guidelines for managing this disease. The results suggest that treatment should be tailored based on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the main treatment, while the use of doxycycline and dapsone is controversial. B-cell-depleting therapy and intravenous immunoglobulins can be considered in treatment-resistant cases. The final version of the guideline received consent from several patient organizations.
Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. Results Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据